Quantcast

Latest Tremelimumab Stories

2013-06-03 12:37:18

The combination of the immunotherapy drug ipilimumab and the investigational antibody drug nivolumab led to long-lasting tumor shrinkage in more than half of patients with metastatic melanoma, according to results from a Phase I trial simultaneously published online on Sunday, June 2, in The New England Journal of Medicine and presented by Memorial Sloan-Kettering Cancer Center researchers at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO). Several patients...

c7d7d7588c7904c027290ba4e1c2ec19
2011-06-06 12:35:00

A new study found that people with advanced melanoma who were treated with Bristol-Myers Squibb Co.'s Yervoy plus chemotherapy lived an average of two months longer than people who got chemotherapy alone. The study is the first to show that combining chemotherapy and an immune-system treatment is safe and effective for patients with advanced melanoma. It is also the second major trial to show Yervoy (ipilimumab), a new type of immunotherapy drug, can improve survival in patients with the...

2011-04-05 08:00:00

CAMBRIDGE, Mass., April 5, 2011 /PRNewswire/ -- Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by normalizing the immune response, today presented results from preclinical studies with 2F8, a murine analog of TRX518, a first-in-class immunomodulatory agent currently in a Phase 1 clinical study for the treatment of cancer. Preclinical data demonstrated anti-tumor efficacy in a murine model as a monotherapy, and further enhanced...

2011-03-25 19:04:34

First drug approved in more than a decade The U.S. Food and Drug Administration today approved the use of ipilimumab for the treatment of previously treated metastatic melanoma. It is the first drug approved for metastatic, or advanced, melanoma is more than a decade. "Ipilimumab is the first in a new class of drugs that has been shown to offer a survival benefit for metastatic melanoma, which is often a fatal disease, and hopefully, this will lead to the development of related treatments for...

2010-05-20 07:00:00

NEW YORK, May 20 /PRNewswire-FirstCall/ -- Pfizer Oncology (NYSE: PFE) will present new data highlighting the company's focused approach to cancer drug development through the identification and validation of molecular targets. These results will be presented at the 46th Annual American Society of Clinical Oncology (ASCO) meeting in Chicago from June 4-8. (Logo: http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO ) "Pfizer Oncology is committed to applying discoveries from cancer...

2009-03-26 11:51:00

PRINCETON, N.J., March 26 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) today announced that Dr. Geoffrey M. Nichol, Senior Vice President of Product Development at Medarex presented highlights from key programs in Medarex's oncology portfolio at the Needham & Company Cancer Therapeutics: Today & Tomorrow Conference in New York. The archived edition of the presentation webcast is available in the Investor Relations section of the Medarex website at www.medarex.com....

2008-09-16 12:00:49

Bristol-Myers Squibb Company and Medarex have announced updated survival data from three Phase II studies of ipilimumab in patients with advanced metastatic melanoma who had previously been treated. Study results show that approximately half of patients who received ipilimumab (10mg/kg) remained alive beyond one year. The results are based on follow-up of the patient population from studies 008, 022 and 007 treated with 10mg/kg of ipilimumab (induction and maintenance) and show a consistent...

2008-09-08 18:00:09

Pfizer announced today that important study results involving the company's leading anticancer agent, SUTENT(R) (sunitinib malate), as well as data examining an investigational agent, CP-751,871, will be presented at the 33rd European Society for Medical Oncology (ESMO) Congress in Stockholm, 12--16 September 2008. Researchers will present results of several analyses evaluating the cost effectiveness of SUTENT(R) as first-line therapy in patients with metastatic renal cell carcinoma...

2008-08-15 09:01:04

Oncolytics Biotech has announced that the US National Cancer Institute, part of the National Institutes of Health, has started enrollment in a Phase II clinical trial for patients with metastatic melanoma using systemic administration of Reolysin, Oncolytics's proprietary formulation of the human reovirus. The trial is being carried out by the Mayo phase two consortium under the National Cancer Institute's (NCI's) clinical trials agreement with Oncolytics, while Oncolytics will provide...


Word of the Day
omphalos
  • The navel or umbilicus.
  • In Greek archaeology: A central boss, as on a shield, a bowl, etc.
  • A sacred stone in the temple of Apollo at Delphi, believed by the Greeks to mark the 'navel' or exact center-point of the earth.
'Omphalos' comes from the ancient Greek.
Related